This filing contains no material financial data or guidance changes. Monitor future filings for any operational or pipeline updates that could affect the stock.
Price Chart
Executive Summary
BridgeBio Oncology Therapeutics filed an 8-K reporting the resignation of board member Michelle Doig effective June 16, 2026, upon completion of her term as a Class I director, and disclosing results from the 2026 Annual Meeting of Stockholders. Director nominees Peter Lebowitz and Frank P. McCormick were elected, and Deloitte & Touche was ratified as the independent auditor. This is a routine governance filing with no material financial impact.
Key Facts
- Michelle Doig resigned from the Board effective June 16, 2026, upon completion of her term as a Class I director; resignation not due to any disagreement with the company.
- At the Annual Meeting, 48,344,441 shares were present or represented by proxy out of 80,112,725 entitled to vote.
- Peter Lebowitz was elected with 31,822,504 votes for and 3,372 withheld; Frank P. McCormick was elected with 25,654,119 votes for and 6,171,757 withheld.
- Ratification of Deloitte & Touche as independent auditor passed with 34,535,875 votes for, 3,440 against, and 0 abstentions.
- There were 2,713,439 broker non-votes and 13,805,126 no votes on the director election proposal.
Financial Impact
No financial impact; routine director resignation and shareholder vote results.
Risk Factors
- No material risks identified from this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-277513 |
| Document: 0001193125-26-277513-index-headers.html | 0001193125-26-277513 |
| Document: 0001193125-26-277513-index.html | 0001193125-26-277513 |
| Document: 0001193125-26-277513.txt | 0001193125-26-277513 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 6w ago | EFFECT | $4.95 $3.31 | ▲ +33.13% | ▲ +35.00% | $2.69 (+45.66%) |
Sep 9, 2026 6w ago | EFFECT | $6.76 $3.44 | ▼ −49.07% | ▼ −51.27% | $2.69 (−60.18%) |
Aug 15, 2026 10w ago | Institutional Cluster | $9.04 $4.88 | ▲ +46.02% | ▲ +44.04% | $2.69 (+70.24%) |
Aug 11, 2026 11w ago | Press Release | $9.42 $5.52 | ▼ −41.40% | ▼ −39.50% | $2.69 (−71.44%) |
Jun 22, 2026 18w ago | 8-K | $7.50 $8.42 | ▲ +12.27% | ▲ +11.11% | $2.69 (−64.13%) |
May 12, 2026 24w ago | Press Release | $8.08 $7.46 | ▼ −7.67% | ▼ −7.06% | $2.69 (−66.71%) |
Apr 21, 2026 27w ago | Press Release | $8.87 $8.72 | ▼ −1.69% | ▼ −4.86% | $2.69 (−69.67%) |
Apr 20, 2026 27w ago | Press Release | $9.46 $8.75 | ▼ −7.51% | ▼ −12.42% | $2.69 (−71.56%) |
Mar 6, 2026 33w ago | Press Release | $10.42 $8.91 | ▼ −14.49% | ▼ −12.45% | $2.69 (−74.18%) |
Mar 5, 2026 33w ago | 8-K | $10.42 $8.91 | ▼ −14.49% | ▼ −12.45% | $2.69 (−74.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers